Fludarabine

Generic Name: Fludarabine

Brand Names: Fludara

Drug Type: Small Molecule

Chemical Formula: C_₁₀H_₁₂FN_₅O_₄

CAS Number: 21679-14-1

Unique Ingredient Identifier: P2K93U8740

Background: Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara.

Indication: For the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen

Associated Conditions: B-cell chronic lymphocytic leukemia/prolymphocytic leukemia/small lymphocytic lymphoma refractory, Refractory Non-Hodgkin's lymphoma

Associated Therapies: -

Clinical Trials

Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant

Phase 2

Recruiting

Conditions: Acute Biphenotypic Leukemia
Acute Leukemia
Acute Leukemia of Ambiguous Lineage
Acute Lymphoblastic Leukemia
Acute Undifferentiated Leukemia
Allogeneic Hematopoietic Stem Cell Transplantation Recipient
Blastic Plasmacytoid Dendritic Cell Neoplasm
Blasts Under 25 Percent of Bone Marrow Nucleated Cells
Blasts Under 5 Percent of Bone Marrow Nucleated Cells
Mixed Phenotype Acute Leukemia

Interventions: Radiation: Total-Body Irradiation
Drug: Thiotepa
Drug: Fludarabine
Drug: Cyclophosphamide
Drug: Busulfan
Drug: Tacrolimus
Procedure: Allogeneic Bone Marrow Transplantation
Drug: Methotrexate
Procedure: Naive T Cell-Depleted Hematopoietic Stem Cell Transplantation
Procedure: Echocardiography
Procedure: Biospecimen Collection
Procedure: Bone Marrow Aspiration
Procedure: Bone Marrow Biopsy

First Posted Date: 2018-12-19

Last Posted Date: 2024-11-14

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 68

Registration Number: NCT03779854

Locations: 🇺🇸
Children's Hospital of Los Angeles, Los Angeles, California, United States
🇺🇸
Children's National Medical Center, Washington, District of Columbia, United States
🇺🇸
Children's Healthcare of Atlanta, Atlanta, Georgia, United States

and more 7 locations

MG4101 Plus Rituximab Including Lymphodepletion in Patient With r/r NHL B-cell Origin

Phase 1

Conditions: Relapsed Non Hodgkin Lymphoma
Refractory Non-Hodgkin Lymphoma

Interventions: Drug: Rituximab
Drug: Fludarabine
Drug: Cyclophosphamide
Biological: MG4101(allogeneic Natural Killer cell)
Drug: Interleukin-2

First Posted Date: 2018-12-19

Last Posted Date: 2020-07-28

Lead Sponsor: GC Cell Corporation

Target Recruit Count: 9

Registration Number: NCT03778619

Locations: 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
🇰🇷
Seoul National Univ. Hospital, Seoul, Korea, Republic of

Study to Evaluate the Efficacy and Safety of Axicabtagene Ciloleucel as First-Line Therapy in Participants With High-Risk Large B-Cell Lymphoma

Phase 2

Completed

Conditions: B-cell Lymphoma

Interventions: Biological: Axicabtagene Ciloleucel
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2018-12-03

Last Posted Date: 2024-12-04

Lead Sponsor: Kite, A Gilead Company

Target Recruit Count: 42

Registration Number: NCT03761056

Locations: 🇺🇸
Banner Health MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇫🇷
Hopital Saint Louis, Paris, France

and more 4 locations

Safety and Efficacy of Repeat Administration of Ad/PNP and Fludarabine Phosphate in Patients With Local Head/Neck Cancer

Phase 1

Active, not recruiting

Conditions: Recurrent Head and Neck Cancer

Interventions: Biological: Ad/PNP
Drug: Fludarabine Phosphate

First Posted Date: 2018-11-27

Last Posted Date: 2024-10-24

Lead Sponsor: GeoVax, Inc.

Target Recruit Count: 8

Registration Number: NCT03754933

Locations: 🇺🇸
Stanford University, Stanford, California, United States
🇺🇸
Winship Cancer Institute - Emory University School of Medicine, Atlanta, Georgia, United States
🇺🇸
Thomas Jefferson University, Philadelphia, Pennsylvania, United States

Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients

Phase 1

Recruiting

Conditions: Rectal Cancer
Colon Cancer
Gastric Cancer
Gastrointestinal Cancer
Pancreatic Cancer

Interventions: Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Aldesleukin
Biological: anti-KRAS G12D mTCR PBL

First Posted Date: 2018-11-19

Last Posted Date: 2024-11-25

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 70

Registration Number: NCT03745326

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL)

Phase 1

Terminated

Conditions: Precursor Cell Lymphoblastic Leukemia-Lymphoma
Lymphoma, Non-Hodgkin

Interventions: Drug: JCAR017
Drug: Lymphodepleting
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2018-11-16

Last Posted Date: 2024-08-15

Lead Sponsor: Celgene

Target Recruit Count: 21

Registration Number: NCT03743246

Locations: 🇺🇸
Local Institution - 167, Redwood City, California, United States
🇺🇸
Local Institution - 161, Seattle, Washington, United States
🇺🇸
Local Institution - 165, Houston, Texas, United States

and more 16 locations

Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma

Phase 1

Recruiting

Conditions: Osteosarcoma
Neuroblastoma

Interventions: Biological: iC9.GD2.CAR.IL-15 T-cells
Drug: Cyclophosphamide
Drug: Fludarabine

First Posted Date: 2018-10-26

Last Posted Date: 2024-10-24

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Target Recruit Count: 18

Registration Number: NCT03721068

Locations: 🇺🇸
Emory - Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States

Clinical Study of CAR-BCMA T in Patients With Refractory or Relapsed Multiple Myeloma

Phase 1

Conditions: Refractory or Relapsed Multiple Myeloma

Interventions: Genetic: CAR-BCMA T cells
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2018-10-23

Last Posted Date: 2020-10-08

Lead Sponsor: First Affiliated Hospital of Zhejiang University

Target Recruit Count: 11

Registration Number: NCT03716856

Locations: 🇨🇳
First Affiliated Hospital of Zhejiang University, Hangzhou, Zhejiang, China

CS1-CAR T Therapy Following Chemotherapy in Treating Patients With Relapsed or Refractory CS1 Positive Multiple Myeloma

Phase 1

Recruiting

Conditions: Refractory Plasma Cell Myeloma
Recurrent Plasma Cell Myeloma

Interventions: Procedure: CS1-CAR T Therapy
Drug: Cyclophosphamide
Drug: Fludarabine
Procedure: Leukapheresis

First Posted Date: 2018-10-18

Last Posted Date: 2024-12-04

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 30

Registration Number: NCT03710421

Locations: 🇺🇸
City of Hope Medical Center, Duarte, California, United States

Anti-CD19/BCMA Bispecific CAR-T Cell Therapy for R/R MM

Phase 1

Conditions: Multiple Myeloma in Relapse
Multiple Myeloma Progression

Interventions: Biological: anti-CD19/BCMA CAR-T cells
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2018-10-16

Last Posted Date: 2018-10-16

Lead Sponsor: Peng Liu

Target Recruit Count: 20

Registration Number: NCT03706547

Locations: 🇨🇳
Department of Hematology ,Fudan University Zhongshan Hospital, Shanghai, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy